Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine Sulphate in Disorders of Consciousness
NCT06443827Phase 2Completed
- Sponsor
- Azienda Sanitaria dell'Alto Adige
- Start
- Sep 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of amantadine hydrochloride intravenous solution in disorders of consciousness (DoC), sponsored by Azienda Sanitaria dell'Alto Adige. Primary endpoints: Coma Recovery Scale-Revised at 28 days and EEG band power alpha, beta, theta, delta at 28 days. Started Sep 2018; status: completed.
02
Drugs
amantadine hydrochloride intravenous solution
03
Conditions
disorders of consciousness (DoC)
Beyond the preview
Go deeper on NCT06443827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443827.